Valuation
- Market cap
- 130,867,000
- Revenue TTM
- $5,820,000
- Net income TTM
- $71,180,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 1,223.02%
- Debt to equity
- 0.12
Trading
- Volume
- 3,176,400
- Avg volume
- 1,711,340
- Day's range
- $2.09 – $2.43
- Shares out
- 57,147,000
- Stochastic %K
- 14%
- Beta
- 1.50
- Analysts
- Strong Buy
- Price target
- $15.56
Company profile
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-...
Show more
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 813 4701
- Website
- https://www.abeonatherapeutics.com
- Address
- 6555 Carnegie Avenue, 4th Floor, Cleveland, United States
Latest news
No headlines yet.
